Kornimate/medical-research-clean huggingface dataset:
dapagliflozin efficacy and action in pcos

Conditions: Polycystic Ovary Syndrome

Summary: the purpose of this study is to assess the efficacy and safety of dapagliflozin on improving insulin resistance and hyperandrogenemia in obesity women with polycystic ovary syndrome.


Eligibility criteria:
inclusion criteria: 1. women aged 18 to 45 years; 2. subjects with pcos diagnosed by according to the rotterdam criteria; 3. bmi ≥24 kg/m2 and/ or homeostatic model assessment of insulin resistance (homa-ir) with a cutoff ≥2.5; 4. no pregnancy plan within the next 6 months; exclusion criteria: 1. congenital adrenal hyperplasia such as 21-hydroxylase deficiency, hyperprolactinemia, cushing syndrome, androgen-producing tumors of the adrenal gland or ovary; 2. other endocrine diseases include poorly controlled thyroid diseases (hyperthyroidism or hypothyroidism), acromegaly, type 2 diabetes; 3. patients with a history of acute / chronic infection, severe cardio-cerebrovascular diseases and acute / chronic pancreatitis; 4. taking any antidiabetic medication that would affect insulin resistance or hyperandrogenemia (i.e. tzd, glp-1ra, dpp-4i, metformin) in the past one month; 5. taking letrozole, clomiphene, oral contraceptive, glucocorticoid, gonadotropin, gonadotropin releasing hormone agonist, anti-androgen drug (spironolactone, cycloproterenone acetate, flutamide etc.) and/or other drugs for pcos in the past three months; 6. history of recurrent urinary tract infection; 7. history of malignant tumor; 8. currently participating in weight loss programs or weight change in the past 3 months (\> 5% current body weight) or have a history of gastrointestinal surgery. 9. serious liver dysfunction or chronic kidney disease (ast or alt \> 3 times the upper limit of normal, or egfr\<30 ml/min/1.73 m2); 10. women who are pregnant or plan to become pregnant; 11. subject is, in the judgment of the investigator, unlikely to comply with the protocol or has any severe concurrent medical or psychological condition that may affect the interpretation of efficacy or safety data; 12. participation in other clinical trial in the 4 weeks before randomization; 13. patients who are unwilling or unable to give informed consent.

Keywords: polycystic ovary syndrome sglt2 inhibitor
effect of nk cell immunotherapy on advanced lung adenocarcinoma adenocarcinoma with egfr mutation

Conditions: NK Cell Mediated Immunity

Summary: this study was attempted to investigate the efficiency of nk cells immunotherapy on non-small cell lung cancer with and without egfr mutation, and evaluated response rate (rr) and the progression-free survival (pfs).

investigators will enrolle 100 patients who met the enrollment criteria. 50 patients were clinically confirmed egfr mutation positive. they were divided into two groups (group a and group c according to if accepted nk therapy) in accordance with the principles of randomized. the rest 50 patients which were egfr mutation negative were also divided into two groups (group b and group d) in accordance with the principles of randomized to be paired respectively with group a and group c. comparison of lymphocyte number, serum tumor related biomarkers, circulating tumor cell (ctc), kps and survival curves was carried out before after nk cell immunotherapy. the safety and short-term effects were evaluated followed by the median pda, response rate assessment.

Eligibility criteria:
inclusion criteria: the criteriaof the enrollment are as following: (1) expected survival\>6 months; (2) age between35-75 years old; (3) kps \>45; (4) platelets\>80 × 109/l, wbc\>3 × 109/l, hemoglobin\>90g/l, prothrombin time-international normalized ratio (0.8-1.5), adequate hepatic function (bilirubin \< 20 μm, aminotransferase\<60 u/l) and renal function (serum creatinine \< 130 μm, serum urea \<10 mm); (5) all patients confirmed by pathology and/or imaging; exclusion criteria: the absence of level 3 hypertension, severe coronary disease, myelosuppression, respiratory disease, acute or chronic infection, and autoimmune diseases. -
a randomized prospective analysis of time to diagnosis and length of stay of emergency department pelvic ultrasonography

Conditions: Pregnancy

Summary: the goal of this project is to compare the efficiency of pelvic ultrasounds performed by emergency medicine residents and attending physicians to the efficiency of pelvic ultrasounds performed by the department of radiology.

this study is a randomized, prospective interventional study of pregnant patients presenting to the emergency department with complaints of pelvic pain and/or vaginal bleeding. this study will be conducted at 4 sites across the united states. patients who are eligible and consent to participate will be randomized to one of two conditions; 1) a pelvic ultrasound that is performed by a certified emergency department attending or physician, or 2) a pelvic ultrasound that is performed by a certified radiology technician (standard-of-care). the time to diagnosis and emergency department length of stay between the two groups will be compared.

Eligibility criteria:
inclusion criteria: * have a positive serum or urine beta-human chorionic gonadotropin (hcg) * estimated gestational age (ega) of less than 20 weeks * complaint of pelvic pain and/or vaginal bleeding exclusion criteria: * prior known documentation of an intrauterine pregnancy * estimated gestational age (ega) of greater than 20 weeks * peritoneal findings on physical examination * unstable vital signs as deemed appropriate by the attending physician * prisoners * open cervix upon physical examination

Keywords: ultrasonography emergency department
abdominal muscle exercises on nocturia and sleep quality in women with type 2 diabetes

Conditions: Nocturia; Sleep Deprivation

Summary: nocturia is the leading cause of sleep disruption with its subsequent negative impact on general health and qol for a large proportion of the adult population. nocturia is prevalent in men and women of all ages but may be particularly bothersome in younger adults, in whom the consequences of sleep disturbance may be more detrimental for daytime functioning and possibly for health and mortality.the underlying causes of nocturia obviously influence the efficacy of different treatment options. because a major cause of nocturia is overproduction of urine at night, nocturia may not respond to treatments designed to reduce urgency and increase bladder capacity or increase urine flow, such as agents for the management of bladder outlet obstruction.

nocturia may be more than simply a patient inconvenience, in view of its association with increased risk of morbidity and mortality. clinicians often underestimate the consequences of nocturia, however, and thus fail to perform a thorough evaluation of the condition and its causes. patients with nocturia deserve full consultation and implementation of an appropriate management strategy to ensure that the specific underlying medical conditions associated with nighttime voiding are addressed. investigators should help women with nocturia as to improve their sleep. participants will strengthen their pelvic floor muscles and abdominal muscles to control voiding so their sleep will not disturb to decrease their sufferance.

Eligibility criteria:
inclusion criteria: * female patients have had type ii diabetes mellitus for more than 5years. * hba1c value from 6.5% to7.5%. * sleep deprivation for more than one month. * medically stable patients * blood glucose level from 130 to 150 * patients are not pregnant * body mass index is 25 to 29.9 kg / m exclusion criteria: * unstable medical condition. * on antidepressors or anxiety treatment. * with ant musculoskeletal or neurological conditions that might interfere with the execution or the assessment of the exercise. * cushing's disease (hypercortisolism) or addison's disease (hypocortisolism).

Keywords: nocturia sleep deprivation sleep quality type 2 diabetes mellitus
screening for atrial fibrillation in native americans using iphone ecg

Conditions: Atrial Fibrillation

Summary: atrial fibrillation (af) is the most common clinically significant arrhythmia and is associated with increased rates of stroke, heart failure, mortality, hospitalization, and cognitive decline. approximately one third of ischemic strokes are attributable to either previously known or newly detected af at the time of stroke. many af episodes are asymptomatic and stroke is the first manifestation of af in at least 25% of af-related strokes. anticoagulation for af leads to a reduction in stroke to levels similar to matched individuals without af. therefore, identifying af in an earlier asymptomatic state (i.e. screening for silent af), with subsequent initiation of anticoagulation in at-risk individuals, may decrease the risk of future thromboembolic events. the availability of inexpensive smartphone-based or handheld ecg devices that rapidly acquire a cardiac rhythm strip of quality comparable to a traditional 12-lead ecg have markedly enhanced the feasibility of af screening. native americans have a high prevalence of diabetes and higher incidence of stroke than whites and blacks. our central hypothesis is that screening for af using a single time point, 30-second iphone-based ecg recording over 2 weeks will result in identification of silent af in a significant number of individuals at risk for stroke compared to routine care (no screening) and will thus lead to improved outcomes through initiation of anticoagulation. the aim of this study is to screen for af in native americans who are seen at the absentee shawnee tribal clinic using a smartphone-based ecg device. individuals who are at least 50 years old and have no prior history of af will be eligible for enrollment in the study. eligible participants will receive a 30-second ecg recording during their visit at the absentee shawnee tribal clinic. the device has an algorithm for diagnosis of af, which is 98% sensitive and 97% specific. a cardiologist will overread the tracings that are diagnosed by af by the device. those confirmed to have af will be referred to a cardiologist for further evaluation and management. the clinical characteristics of those who are found to have af will be compared with those who are not, in order to identify risk factors for af. newly diagnosed af using this method is expected to be approximately 2.5%. we aim to include a total of 1,500 participants over 12 months. the proposed study will provide the basis for the design of further intervention studies using mobile technology to improve the health of native americans and other minority populations. in light of the high prevalence of risk factors for af in native americans and the association of silent af with stroke, this novel approach for af screening has the potential to impact clinical practice and improve health outcomes among a large number of individuals.


Eligibility criteria:
inclusion criteria: * male or female aged 50 or older exclusion criteria: * known history of atrial fibrillation
iyengar yoga for young people with irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: irritable bowel syndrome (ibs) affects as many as 14% of high school-aged students. symptoms include discomfort in the abdomen, along with diarrhea and/or constipation and other gastroenterological symptoms, which can significantly impact quality of life and daily functioning of patients. emotional stress appears to exacerbate ibs symptoms suggesting that mind-body interventions reducing arousal may prove beneficial. often symptoms can be traced to childhood and adolescence, making the early manifestation of ibs important to understand. the current study focuses on young people aged 14-26 years of age with ibs. the study will test the potential benefits of iyengar yoga (iy) on clinical symptoms, psychospiritual functioning and visceral sensitivity. yoga is thought to bring physical, psychological and spiritual benefits to practitioners and has been associated with reduced stress and pain. through its focus on restoration and use of props, iy is especially designed to decrease arousal and promote psychospiritual resources in physically compromised individuals. sixty-four ibs patients aged 14-26 will be randomly assigned to a standardized 6-week biweekly iy group-based program (1.5 hour sessions) or a wait-list usual care control group. the groups will be compared on the primary clinical outcomes of ibs symptoms, quality of life and global improvement at post-treatment and 2 month follow-up. secondary outcomes will include visceral pain sensitivity assessed with a standardized laboratory task (water load task), and psychospiritual variables including coping, self-efficacy, mood, acceptance and mindfulness. it is hypothesized that iy will be safe and feasible: with less than 20% attrition; and the iy group will demonstrate significantly improved outcomes compared to controls, with physiological and psychospiritual mechanisms contributing to improvements; clinical treatment gains will be maintained at 2 months following yoga.


Eligibility criteria:
inclusion criteria: * male and female youth will be eligible for the study if they meet the following criteria: * age 14-26 years. * diagnosis of ibs, using rome iii pediatric criteria for patients aged 14-17 years, and rome iii adult criteria for 18-26 year-olds. * able and willing to give written informed assent or consent and comply with the requirements of the study protocol. * ability to speak and understand english. exclusion criteria: * any other injury, disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion that it might affect the interpretation of the results or render the patient at high risk from treatment complications. * inability to comply with study and follow-up procedures. * currently pregnant. * previous practice of yoga within the past three months. * inability to speak and understand english. * plan to begin a new treatment within 2 weeks of the iyp.
intratracheal budesonide with surfactant to prevent bronchopulmmonary dysplasia.

Conditions: Bronchopulmonary Dysplasia; Respiratory Distress Syndrome in Premature Infant; Prematurity

Summary: this study is designed to determine whether intratracheal administration of budesonide combined with surfactant, as compared to surfactant alone, will modify ecographic (lung ultrasound score) and biological markers (il-6 concentration in respiratory secretions) at 7 days of life in preterm infants ≤32 weeks of gestational age (ga).

bronchopulmonary dysplasia (bpd) is one of the main morbidities associated with extreme prematurity and, despite the improvement of respiratory care in the latest years, overall incidence is not decreasing. etiology of bpd is multifactorial and local inflammation plays an important role in it, therfore, local anti-inflammatory drugs could be effective in preventing bpd. recent randomised trials have shown a lower incidence of bpd/death with the use of a combination of budesonide with surfactat compared to surfactant alone, and further clinical trials are currently ongoing. this is a controlled phase iv, randomised, unicenter clinical trial designed to evaluate the effect of intratracheal administration of budesonide combined with surfactant, as compared to surfactant alone, in bpd in preterm infants ≤32 weeks of ga. investigators will compare ecographic and biological markers, as well as respiratory outcomes.

Eligibility criteria:
inclusion criteria: * infants born equal or earlier than 32 weeks of gestational age admitted in the neonatal intensive care unit. * parental consent signed. * less than or equal to 48 hours postnatal age. exclusion criteria: * infants with known major congenital anomalies (eg. congenital upper airwayobstruction, congenital lung anomaly, severe pulmonary hypoplasia, hydrops,neuromuscular diseases, chromosomopaties) * infants with poor prognosis and risk of imminent death * infants who have received the first dose of surfactant before of the enrolment to the study.

Keywords: bronchopulmonary dysplasia respiratory distress syndrome in premature infant prematurity lung injury poractant alfa pulmonary surfactant budesonide anti-inflammatory agents glucocorticoids lung ultrasound il-6
efficacy and safety of biphasic insulin aspart 30 in type 2 diabetes mellitus when failing on oads

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe. this is a clinical trial investigating the effectiveness and the safety of using biphasic insulin aspart 30 both for initiation and intensification of insulin treatment in type 2 diabetes.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus for more than 12 months * hba1c: 7.5 - 11.0% * an antidiabetic regimen that has been stable for at least 3 months prior to screening * an antidiabetic regimen that includes a minimum of 2 oral anti-diabetic drugs (oads) or 1 oad plus evening or bedtime basal insulin * oads dosed at 50% or more of the maximum recommended dose exclusion criteria: * use of any insulin preparations other than nph or glargine within the past 6 months * use of more than 60 units of insulin per day * morning time insulin administration * use of more than one insulin dose daily
microvascular decompressive surgery for hemifacial spasm

Conditions: Hemifacial Spasm

Summary: * review the clinical outcomes of micro vascular decompression of hemi facial spasm. * assess safety and efficacy of micro vascular decompression. * improve the outcome of these patients and decease rate of recurrence and complications.

hemi facial spasm (hfs), a term described in 1905 by babinski but first reported by schultz in 1875, is a highly morbid movement disorder characterized by intermittent involuntary movement of muscles innervated by the facial nerve. (hfs) affects roughly 10 in 100,000 individuals in fifth or sixth decades of life. primary hfs is commonly attributed to vascular loops compressing the seventh cranial nerve at its exit zone from the brainstem. the facial nerve compression is thought to lead to ephaptic transmission and to hyperactivity of the facial nucleus, resulting in the involuntary facial movements. secondary hfs frequently follows peripheral facial palsy or may arise from facial nerve damage produced by tumours, demyelinating disorders, traumatisms, and infections accounting for 1-2 \& of hfs. over four in five primary hfs cases involve either anterior or posterior inferior cerebellar artery as the primary offender although vertebral artery, multiple vessels and veins may be involved. emg recordings confirm the diagnosis by showing a typical electrophysiological signature: clonic facial muscle contractions, hyperactivity, and synkinesis, lateral spread evoked responses. imaging can be useful for confirming that hfs is primary in nature and due to a neurovascular compression. in most cases (95% of the patients) the compressive vessel, generally an artery, is seen on mri combined with mr-angiography (mra). high resolution t2-sequence is to be used to get good delineation of the facial nerve. many treatments for hfs have been reported, including pharmacological agents, botulinum toxin injection, facial nerve blockage, physical therapy, radiofrequency ablation, acupuncture, as well as facial nerve combing and microvascular decompression (mvd). however, while mvd is effective, there are still significant postoperative complications.

Eligibility criteria:
inclusion criteria: primary hemi facial spasm unilateral adults 20-60 years clinical diagnosis confirmed by facial evoked potential \& neuroimaging exclusion criteria: secondary hemi facial spasm caused by intracranial masses or other lesions recurrent hemi facial spasm patients who are unfit for any neurosurgical interventions.
apoptosis may have a role in etiopathogenesis of obstetric cholestasis.

Conditions: Pregnancy

Summary: intrahepatic cholestasis of pregnancy is a disease specific to pregnancy period; especially late second and third trimester. we aimed to investigate the role of apoptosis in etiopathogenesis of obstetric cholestasis.

m30 (caspases cleaved cytokeratin-18 (ck-18) fragment) is a specific apoptosis marker. we aimed to use it to evaluate the apoptotic process.

Eligibility criteria:
inclusion criteria: * late second or third trimester of pregnancy. exclusion criteria: * foreknown systemic diseases, multiple pregnancy, smoking cigarettes.

Keywords: apoptosis intrahepatic cholestasis obstetric outcomes
effect of the administration of l-carnitine on body weight in women in crossfit training

Conditions: Body Weight Changes

Summary: the l-carnitine has demonstrated effects in the treatment of obesity mainly promoting the fat degradation during exercise.

a randomized, double-blind, placebo-controlled clinical trial will be carry out in 24 woman with body mass index ≥ 25 to 29.9 kg/m2. the patients will receive 1.5 g of l-carnitine deluded in 250 ml of water or placebo before crossfit training, 5 times a week for 8 weeks. before and after intervention the investigators evaluate: the body composition (body fat, lean body mass), arm muscle circumference, waist circumference, body weight and body mass index.

Eligibility criteria:
inclusion criteria: * volunteers who practice crossfit regularly (who have 3 months prior to the beginning of the study practicing crossfit). * volunteers with a body mass index equal to or greater than 25 kg/m2. * volunteers who do not have allergies to l-carnitine or any of its components. * informed consent signed * women with a recommendation of nutrition two weeks prior to the start of the study. * body weight stable the last 3 months. exclusion criteria: * volunteers with pathologies such as diabetes, hypertension, metabolic syndrome and allergies. * women with confirmed or suspected pregnancy. * women under lactation and/or puerperium. * hypersensibilility to l-carnitine or sucralose. * kown of renal, hepatic or thyroid deseased. * current or previous treatment diet (3 months before inclusion to the study). * current pharmacological treatment for loose body weight or 3 months before inclusion to the study.

Keywords: overweight obesity l-carnitine body weight body fat percentage